Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Join Barchart Premier to get Screeners that run automatically with the results emailed to you! FREE 30 Day Trial
Stocks | Futures | Watchlist | News | More
or
Faster, Cleaner, Better.

Becton Dickinson and Company (BDX)

Becton Dickinson and Company (BDX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NYSE]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NYSE]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 59,836,376
  • Shares Outstanding, K 284,908
  • Annual Sales, $ 21,840 M
  • Annual Income, $ 1,678 M
  • EBIT $ 2,578 M
  • EBITDA $ 5,040 M
  • 60-Month Beta 0.25
  • Price/Sales 2.69
  • Price/Cash Flow 8.95
  • Price/Book 2.33

Options Overview Details

View History
  • Implied Volatility 38.88% (+3.89%)
  • Historical Volatility 20.32%
  • IV Percentile 99%
  • IV Rank 93.19%
  • IV High 40.49% on 04/10/25
  • IV Low 16.81% on 02/11/25
  • Expected Move (DTE 12) 13.22 (6.29%)
  • Put/Call Vol Ratio 0.68
  • Today's Volume 2,452
  • Volume Avg (30-Day) 586
  • Put/Call OI Ratio 0.29
  • Today's Open Interest 23,316
  • Open Int (30-Day) 24,400
  • Expected Range 196.80 to 223.24

Analyst Rating / Earnings Estimates

Current Rating
See More
Moderate Buy
Based on 13 analysts offering recommendations.
Earnings Estimates - Current Qtr 12/31/25
See More
  • Average Estimate 2.82
  • Number of Estimates 7
  • High Estimate 2.85
  • Low Estimate 2.79
  • Prior Year 3.43
  • Growth Rate Est. (year over year) -17.78%

Price Performance

See More
Period Period Low Period High Performance
1-Month
195.63 +7.36%
on 01/23/26
213.08 -1.44%
on 02/04/26
+4.66 (+2.27%)
since 01/06/26
3-Month
174.71 +20.21%
on 11/07/25
213.08 -1.44%
on 02/04/26
+32.63 (+18.39%)
since 11/06/25
52-Week
162.29 +29.41%
on 11/06/25
235.34 -10.76%
on 03/10/25
-17.19 (-7.57%)
since 02/06/25

Most Recent Stories

More News
BD Earnings: What To Look For From BDX

BD Earnings: What To Look For From BDX

BDX : 210.02 (+1.70%)
BD and Envetec Demonstrate Closed-Loop Recycling Solution for Laboratory Plastics in Health Care

Study Opens Door to Sustainable Path for Polystyrene Petri Dishes, PET Tubes, Medical Tubing, and Polypropylene Syringes Across Healthcare Supply Chains

BDX : 210.02 (+1.70%)
1 Cash-Producing Stock to Consider Right Now and 2 We Find Risky

1 Cash-Producing Stock to Consider Right Now and 2 We Find Risky

WRB : 70.41 (-1.23%)
BDX : 210.02 (+1.70%)
TNC : 81.97 (+1.40%)
BD Board Declares Dividend, Authorizes 10 Million Additional Share Repurchases; BD Completed $250 Million Repurchase to Date in FY26

FRANKLIN LAKES, N.J. , Jan. 27, 2026 /PRNewswire/ -- The Board of Directors of BD (Becton, Dickinson and Company) (NYSE: BDX), a leading global medical technology company, today announced it has...

BDX : 210.02 (+1.70%)
BD to Announce Financial Results for its First Quarter of Fiscal 2026

FRANKLIN LAKES, N.J. , Jan. 27, 2026 /PRNewswire/ -- BD (Becton, Dickinson and Company) (NYSE: BDX), a leading global medical technology company, today announced that BD management will host an audio...

BDX : 210.02 (+1.70%)
BD Announces Record Date for the Spin-Off of its Biosciences & Diagnostic Solutions Business

Distribution date and closing date for spin-off and merger with Waters Corporation set for February 9, 2026

BDX : 210.02 (+1.70%)
WAT : 381.29 (+1.17%)
Waters Shareholders Approve Combination with BD's Biosciences & Diagnostic Solutions Business

Waters Corporation's Q4 2025 Financial Results Conference Call will now be held on Monday,  February 9 th , 2026 at 8:30am ET in conjunction with the expected close of the transaction...

BDX : 210.02 (+1.70%)
WAT : 381.29 (+1.17%)
Stocks Finish Mostly Higher Despite a Plunge in Intel

The S&P 500 Index ($SPX ) (SPY ) on Friday closed up +0.03%, the Dow Jones Industrials Index ($DOWI ) (DIA ) closed down -0.58%, and the Nasdaq 100 Index ($IUXX ) (QQQ ) closed up +0.34%. March E-mini...

GOOGL : 322.86 (-2.53%)
AAPL : 278.12 (+0.80%)
B : 45.16 (+2.71%)
AVGO : 332.92 (+7.22%)
HL : 22.77 (+6.85%)
SNDK : 597.95 (+3.77%)
CDE : 21.44 (+12.19%)
ADI : 320.45 (-0.52%)
TXN : 221.44 (-1.13%)
$IUXX : 25,075.77 (+2.15%)
ZNH26 : 112-010 (-0.07%)
MSFT : 401.14 (+1.90%)
BD Helps Scientists Advance Immunology and Cancer Research with AI-Powered Insights and Automation

Newest version of BD® Research Cloud features an AI-powered tool for automated panel design to improve quality, efficiency and usability of scientific results across research areas

BDX : 210.02 (+1.70%)
BD and Ypsomed Expand Partnership to Address Rapidly Growing Biologics Market

The enhanced collaboration and innovation will improve options for pharmaceutical companies and patients requiring large-volume self-injection systems

BDX : 210.02 (+1.70%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 100% Buy with a Strongest short term outlook on maintaining the current direction.

Long term indicators fully support a continuation of the trend.

See More Share

Business Summary

Becton, Dickinson and Company, is a medical technology company engaged principally in the development, manufacture and sale of medical devices, instrument systems and reagents. BD's operations consisted of three business segments: BD Medical, BD Diagnostics and BD Biosciences. The company's organizational...

See More

Key Turning Points

3rd Resistance Point 217.98
2nd Resistance Point 214.34
1st Resistance Point 212.18
Last Price 210.02
1st Support Level 206.38
2nd Support Level 202.74
3rd Support Level 200.58

See More

52-Week High 235.34
Last Price 210.02
Fibonacci 61.8% 207.43
Fibonacci 50% 198.82
Fibonacci 38.2% 190.20
52-Week Low 162.29

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.
Free Barchart Webinar